ABSTRACT-We measured the number of D1-receptors (Bmax) in the striatum whose dopaminergic termi nals were destroyed to various degrees by 6-hydroxydopamine (6-OHDA) to clarify the relationship be tween the degree of denervation and the change in Bmax for D1-receptor. Rats were sacrificed 28 days after 6-OHDA treatment, and [3H]SCH23390 (R(+)-7-chloro-8-hydroxy-3-methyl-l-phenyl-2,3,4,5-tetrahydro 1H-3-benzazepine) binding capacity and monoamine content were measured in striatal homogenate. Bmax was significantly upregulated when dopamine content was reduced to less than 5% of that in the vehicle treated striatum. In contrast, it was significantly decreased when dopamine content was 5-25% of that in the vehicle-treated striatum. The D1-receptors showed either upregulation or downregulation depending on the degree of denervation.
The cause of Parkinson's disease is thought to be degeneration of dopaminergic neurons in the substantia nigra. Consequently, dopamine content in the striatum is severely reduced in the disease. 6-Hydroxydopamine (6-OHDA) destroys catecholaminergic terminals after uptake into the terminals. Thus, 6-OHDA has been used to make an animal model of Parkinson's disease.
In general, postsynaptic receptors are upregulated in compensation for decreased release of neurotransmitter when nerve terminals controlling the receptors are damaged. It is well-documented that the D2-receptor is upregulated after denervation of dopaminergic terminals by 6-OHDA. On the contrary, there are controversial results about the 6-OHDA-induced alteration in the number of D1-receptors, as to whether it is decreased (1), increased (2, 3) or unchanged (4). Furthermore, using an autoradiographic assay for D1-receptors, researchers also found an inconsistent alteration in the number of D1 receptors (5 9). There are some reports that attempted to attribute this inconsistency to variations in the time periods used after 6-OHDA treatment (6, 8) . Fornaretto et al. (8) indicated that upregulation of D1-receptors exhibited a longer lag-time than D2-receptors. However, Marshall et al. (6) observed no upregulation of D1-recep tors 2 weeks, 8 weeks or 11 months after 6-OHDA treat ment. We believe that the degree of destruction is another important factor in the upregulation of D1-receptors. Male 8-9-week-old Wistar rats (Japan SLC Co., Hamamatu), weighing 240-260g, were used. The animals were housed with free access to standard food in an air-conditioned room under a constant 12-hr light and dark cycle (lights on at 7:00 a.m.) at a temperature of 22-24C and 60-70% relative humidity. Rats were anesthetized with 50 mg/kg pentobarbital (Nembutal; Abbott Laboratories, North Chicago, IL, USA), s.c. and ether. 6-OHDA (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in 0.9070 saline with 0.1% ascorbic acid. Various doses of 6-OHDA (2.5-60 ,g) were ad ministered into two separate regions of the left striatum using a 10 tl microsyringe (Hamilton Co., Reno, NV, USA) and an infusion pump (Natume Seisakujo Co., Ltd., Tokyo) at a rate of 1.0 it/min. The tip of the syringe was inserted vertically using a stereotaxic appa ratus (Narishige Scientific Instrument Lab., Tokyo) through a small hole in the skull 3-mm lateral to the bregma and 5-mm-deep as measured from the surface of the skull. The second injection was 2-mm rostral to the first lesion. The syringe remained in place for 2 min fol lowing the infusion to minimize the spread of the drug through injection tracks. The volume of the 6-OHDA solution was 2 jd per lesion, and the concentration of 6-OHDA solution was 0.625 15 iglpl. Vehicle was ad ministered into the right striatum, but otherwise its injec tion was performed similarly to the 6-OHDA injection.
Rats were decapitated 28 days after the drug infusion. The striatum of each rat was rapidly removed on an ice cold glass plate and then homogenized by a Polytron (Kinematica Co., Lucerne, Switzerland) at setting 6 for 20 sec in 1 ml of 50 mM Tris/HC1 (pH 7.4), 120 mM NaCI and 5 mM KCl (Tris buffer). Part of the homogenate was used for the protein assay and part for the monoamine assay. The rest of the homogenate was centrifuged at 30,000 x g for 10 min at 4C, and the pellet was used for the binding assays.
[3H]SCH23390
(R(+)-7-chloro-8-hydroxy-3-methyl 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine) (specific activity 316.5 GBq/mmol; Du Pont Co., Boston, MA, USA) was employed as a ligand for specific D,-receptor binding. Striatal membrane (0.1 mg protein; protein con centration, 0.1 mg/ml) was incubated with various con centrations (0. The abscissa is the percent of dopamine (DA) content in 6-OHDA-treated striatum compared with contralateral vehicle treated striatum. The ordinate is the change in BmaX±S.E. in 6 OHDA-treated striatum compared with contralateral vehicle-treated striatum. The number of rats in the groups in which dopamine contents were less than 507o, 5-15070, 15-25% and more than 25070 of the control level was 5, 11, 6 and 4, respectively. *Statistically different from vehicle-treated contralateral striatum as determined by Student's t-test (P<0.05). The ordinate is the change of Bmax±S.E. in 6-OHDA-treated stria tum compared with vehicle-treated striatum. The number of rats whose dopamine content was less than 10070 and 10-20% as com pared with the vehicle-treated contralateral striatum was 6 and 4, respectively. *Statistically different from vehicle-treated contralat eral striatum by Student's t-test (P<0.05).
The striatal homogenate was mixed with 1 ml 0.1 M perchloric acid containing 5 mM ethylenediaminetetra acetic acid (EDTA) and 3,4-dihydroxybenzylamine (DHBA) (Sigma) and stored at -401C. Monoamine content was measured by high-performance liquid chro matography (HPLC) with an electrochemical detector (ECD) as described previously (10).
Protein concentration in striatal homogenate was de termined by the Bradford protein assay using dye reagent purchased from Bio-Rad Laboratories (Hercules, CA, USA). Bovine serum albumin was used as the standard.
There was a significant alteration in the Bmax for D1 receptors in the striatum whose dopamine content was less than 5% compared with contralateral vehicle-treated striatum (Fig. 1) . The Bmax was decreased by 16-17% when the dopamine content was 5-25% of the control. When the dopamine content was greater than 25070 of the control, there was no change in the number of D1-recep tors. Dopamine content (mean±S.E.) in the vehicle treated striatum (n=26) was 129 ± 5.5 ng/mg protein, and Bmax (mean±S.E.)
of the vehicle-treated controls (n=26) was 1,362±66 fmol/mg protein. The Kd for [3H] SCH23390 binding (mean-LS.E.) in 6-OHDA (n=26) and vehicle (n=26)-treated striata were 350-L25 and 360±31 pM, respectively.
On the other hand, D2-receptors were upregulated when the dopamine content was decreased to approxi mately 10% of control level (Fig. 2) . Dopamine content (mean±S.E.) in the vehicle-treated striatum (n= 10) was 139±5.4 ng/mg protein, and the Bmax (mean _-t S.E.) for the vehicle-treated striatum was 615 ±47 fmol/mg protein (n=10). The Kd for 6-OHDA (n=10) and vehicle (n=10)-treated striata were 30.8± 2.3 and 30.6 ± 1.9 pM, respectively.
The [3H]spiperone binding assay showed upregulation of D2-receptors induced by the denervation of dopa minergic terminals. However, the relationship between the degree of denervation in dopaminergic terminals and upregulation of D1-receptors is not simple. The Bmax of [3H]SCH23390 binding was not increased until dopa mine content was reduced by more than 95%. Further more, the Bmax was decreased when the dopamine content was between 5070 and 25070 of the control level. Previous studies indicated that the D1-receptor was upregulated af ter denervation by 6-OHDA when more then 97% of the dopaminergic terminals were destroyed (11). Therefore, prominent dopaminergic terminal denervation is required in order for D1-receptors to be upregulated.
As mentioned earlier, time is an important factor in D1-receptor upregulation. Fornaretto et al. (8) showed that D1-receptors were upregulated 16 to 90 days after 6-OHDA treatment, while D2-receptors were already in creased after 15 days. We sacrificed rats 28 days after treatment, since this should be enough time to observe D2-receptor upregulation (10). It is possible that upregu lated D1-receptors return to the control level after a long er lag-time, e.g., one year as Fornaretto et al. suggested (8). However, we are uncertain if upregulation in moder ately denervated striatum (whose dopamine content was 5-25070 of the control level) can occur longer than 28 days after 6-OHDA.
The Bmax for D1-receptors in rats whose dopamine con tent is less than 5070 of the control showed a 42% increase compared with the Bmax in a group of rats whose dopa mine content was 5-15% of the control. However, the Bmax for 6-OHDA-treated animals is only increased by 19% when expressed as a percentage of the vehicle-treated contralateral striatum. Therefore, if the slight decrease in the Bmax for D1-receptors due to moderate denervation is neglected, only a small increase in Bmax would be seen. That may be one reason other investigators reported no significant change in the number of D1-receptors after denervation by 6-OHDA. Recently, Marcotte et al. (12) suggested one possible explanation for why it is difficult to upregulate D1-receptors. They showed an increase in the D1-receptor-linked G-protein, Gs and Golf, with only a small increase in the D2-receptor-linked G-protein, Gi and Go. They attributed difficulty in upregulation of D1 receptors to the increase in G-proteins coupled to D1 receptors.
We observed a decrease in D1-receptors when the degree of denervation was moderate. This result coincides with several studies in which denervation of dopamin ergic terminals were insufficient. We are unsure as to the mechanism. A decrease in the production of D1-receptors (9, 13), degeneration of dendrites that bear D1-receptors (2), and an alteration in the distribution pattern of D1 receptors (14) have been suggested. However, existence of D1-receptors on dopaminergic terminals is not pos sible, since a decrease in D1-receptors was not observed when dopamine content was greater than 25070 of the control level.
In conclusion, we observed either a decrease or an in crease in D1-receptors after 6-OHDA treatment depend ing on the dose administered. D1-receptors could be up regulated after 6-OHDA treatment as could D2-receptors. 238, 245-250 (1982) 
